Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III comparison of HS-20090 versus Xgeva in patients with bone metastases from solid tumors
CTR20222540Phase 3Active
- Sponsor
- Hengrui Therapeutics
- Start
- Oct 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of HS-20090 in bone metastases (2 arms), sponsored by Hengrui Therapeutics. Primary endpoint: Percent change from baseline in urinary N-telopeptide normalized to creatinine. Started Oct 2022; status: active.
02
Drugs
HS-20090
03
Conditions
bone metastases
Beyond the preview
Go deeper on CTR20222540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222540.